{"filing":{"accession_number":"0001062993-26-003976","cik":"0001833141","ticker":"HELP","company_name":"CYBIN INC.","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"form6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000106299326003976/form6k.htm"},"events":[{"id":23041,"run_id":20860,"accession_number":"0001062993-26-003976","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit announces the appointment of Michael Halstead as Chief Executive Officer of Helus Pharma (Cybin Inc.), effective immediately. Halstead is a highly experienced pharmaceutical executive with 25 years of industry experience, most recently President of Intra-Cellular Therapies, where he led the company through commercialization and its $14.6 billion sale to Johnson \u0026 Johnson. This is a material executive appointment at a critical juncture as the company prepares for Phase 3 topline data readout in Q4 2026.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23178,"accession_number":"0001062993-26-003976","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Michael Halstead as Chief Executive Officer of Helus Pharma (Cybin Inc.), effective immediately. Halstead is a highly experienced pharmaceutical executive with 25 years of industry experience, most recently President of Intra-Cellular Therapies, where he led the company through commercialization and its $14.6 billion sale to Johnson \u0026 Johnson. This is a material executive appointment at a critical juncture as the company prepares for Phase 3 topline data readout in Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:22:41.266534+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23178,"accession_number":"0001062993-26-003976","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Michael Halstead as Chief Executive Officer of Helus Pharma (Cybin Inc.), effective immediately. Halstead is a highly experienced pharmaceutical executive with 25 years of industry experience, most recently President of Intra-Cellular Therapies, where he led the company through commercialization and its $14.6 billion sale to Johnson \u0026 Johnson. This is a material executive appointment at a critical juncture as the company prepares for Phase 3 topline data readout in Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:22:41.266534+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-03"}]}